Expression of PD-1 on peripheral blood Treg cells is related to the diagnosis, prognosis and treatment of T cell non-Hodgkin lymphoma

• Published in: Leukemia research Vol. 70; pp. 56 - 61
• Main Authors: Zuo, Mengxuan, Shen, Haorui, Yin, Jingjing, Wang, Wei, Zhang, Yan, Zhou, Dao-Bin, Zhang, Wei
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.07.2018
• Subjects: Peripheral blood; Programmed death-1; T cell non-Hodgkin lymphoma; Treg cell; T cell non-Hodgkin lymphoma; Treg cell; Peripheral blood; Programmed death-1
• ISSN: 0145-2126; 1873-5835
• DOI: 10.1016/j.leukres.2018.05.008

•PD-1 expression on Tregs in T-NHL patients is higher than that in the healthy.•The higher the PD-1 expression on Tregs, the poorer the prognosis of patients.•After therapy, PD-1 expression on Tregs in T-NHL patients turn to normal. The aim of study was to explore the PD-1 expression on Treg cells and its association with T-NHL. 137 patients newly diagnosed with T-NHL and 115 healthy controls were enrolled. The expression level of PD-1 was measured by flow cytometry at the time of diagnose and 3–8 course of treatment. Median fluorescence intensity (MFI) of PD-1 on Treg cells in T-NHL patients was significantly higher than that in healthy controls (P < 0.001). MFI of PD-1 in medium/high-risk T-NHL patients were higher than that in low-risk patients (P < 0.05). After treatment with Chidamide combined with chemotherapy, MFI of PD-1 significantly decreased (P < 0.05). In patients with high PD-1 expression (percentage>19.6% and MFI > 580), EFS was significantly lower than patients with low PD-1 expression (percentage<19.6% and MFI < 580). The PD-1expression on peripheral blood Treg cells of T-NHL patients is related to the diagnosis, prognosis and treatment of disease.